Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer
Authors:
- 1 June 2001
- journal article
- research article
- Published by Wiley in Pathology International
- Vol. 51 (6) , 452-459
Abstract
Androgen, acting via the androgen receptor (AR), is associated with the development and progression of prostate cancer. Anti‐androgen therapy is widely used to manage prostate cancer. However, the conversion of the tumor from a hormone‐sensitive to a hormone‐insensitive status causes such therapy to fail. Several mechanisms have now been put forward for this conversion, including neuroendocrine (NE) differentiation of the tumor cells. In this study, we evaluated the prognostic significance of tumor‐cell proliferation activity, NE differentiation and AR expression. Formalin‐fixed, paraffin‐embedded sections were prepared from 42 patients with adenocarcinoma of the prostate. Using antibodies to AR, the Ki‐67 antigen (MIB‐1), chromogranin A and synaptophysin, immunohistochemical expression of AR, tumor proliferation activity and NE differentiation were analyzed. Our study revealed that AR expression was significantly lower in adenocarcinoma (52.2 ± 27.1%) than in non‐tumorous prostate tissue (68.3 ± 18.3%; P < 0.001). NE differentiation was found in 50% of the tumors, which was correlated with the Gleason score (P < 0.05). An univariate analysis revealed a significant correlation between progression‐free survival with both AR expression (P < 0.01) and proliferation activity (P < 0.001). NE differentiation was not a prognostic factor in this study.Keywords
This publication has 20 references indexed in Scilit:
- TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLYJournal of Urology, 1998
- Neuroendocrine differentiation and prognosis in prostatic adenocarcinomaBritish Journal of Urology, 1997
- The Prognostic Value of Neuroendocrine Differentiation in Adenocarcinoma of the Prostate in Relation to Progression of Disease After Endocrine TherapyJournal of Urology, 1997
- Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomyHuman Pathology, 1996
- Immunocytochemical assay for androgen receptors in prostate cancer: A prospective study of 63 cases with long-term follow-upAnnals of Surgical Oncology, 1994
- Do neuroendocrine cells in human prostate cancer express androgen receptor?Histochemistry and Cell Biology, 1993
- Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostateVirchows Archiv, 1993
- P53 and Ki‐67 Immunoreactivity in Human Prostate Cancer and Benign HyperplasiaBritish Journal of Urology, 1992
- Neuro‐endocrine Cells—A New Prognostic Parameter in Prostate CancerBritish Journal of Urology, 1991
- Growth fractions in human prostatic carcinoma determined by Ki‐67 immunostainingThe Journal of Pathology, 1988